Skip to content

Validation & Evidence Library · Volume IV, 2024

The audited record behind every BR2H-Score deployed across 2.4 million covered lives.

The dossier benefits consultants, brokers, and risk committees forward to actuarial review — Milliman-audited savings, the 91.3% AUC methodology, 47 peer-reviewed publications, and the governance framework that holds it together.

Last updated
14 October 2024
Reviewing bodies
Milliman · Stanford PRC · KLAS
Document class
Clinical evidence dossier

Headline figures · Audited

The four numbers a benefits consultant must see before forwarding to procurement.

Each figure below traces to a named methodology, study period, and reviewing body — no marketing rounding.

  1. 91.3% AUC for 30-day readmission prediction across 2.4M covered lives. Patented BR2H-Score™ · internal validation cohort 2019–2024
  2. $2,840/PEPY Average reduction in total medical spend, audited across 17 employer deployments. Milliman independent audit · 2022–2024 measurement window
  3. 47papers Peer-reviewed publications co-developed with the Stanford Prevention Research Center. PubMed-indexed · 2021 through Q4 2024
  4. 14/F500 Fortune 500 enterprises deployed BR2H within 18 months of general availability. BR2H enterprise sales ledger · 2023–2024

Methodology · Chaptered Brief

How the BR2H-Score is built, validated, and governed.

A citable technical brief for actuarial review. Each chapter stands alone; together they describe a defensible model with a documented governance surface.

I

Input signals — 180+ passive streams, adjudicated and consented.

The model ingests continuous CGM, HRV, and step-cadence from consented wearables; FHIR-encoded EHR observations; and adjudicated medical, pharmacy, and dental claims. Every signal is timestamped, source-tagged, and routed through a HIPAA-compliant single-tenant lake with HITRUST CSF v11 attestation.

  • CGM
  • HRV
  • Step-cadence
  • FHIR · EHR
  • Adjudicated claims
  • Pharmacy
  • Dental
II

Validation cohort — 2.4M covered lives, 41 months of follow-up.

Model coefficients were trained on 1.7M members and locked before prospective validation across a held-out cohort of 2.4M. The reference AUC of 91.3% for 30-day readmission is reported on the prospective arm only, with confidence intervals published in the State of Workforce Risk 2024 appendix.

Reference: Chen M., Okafor L., et al., JMIR Medical Informatics, 2024.

III

Calibration — isotonic regression, refreshed quarterly.

BR2H-Score outputs are passed through isotonic regression against observed 12-month high-cost events. Calibration refreshes every 90 days using the prior quarter's adjudicated outcomes, with drift monitored via population stability index and PSI-flagged sites returned to the modeling team for retraining review.

IV

Governance — clinical advisory, security attestations, model risk.

A 38-person clinical advisory board signs off on every model release. The platform is SOC 2 Type II, HITRUST CSF v11, ISO 27001, and HIPAA-compliant, audited annually by Coalfire. Production deployments carry a 99.982% uptime SLA, verified by independent third-party monitoring.

  • SOC 2 Type II
  • HITRUST CSF v11
  • ISO 27001
  • HIPAA
  • Coalfire annual audit

Comparison · RFP-ready

BR2H-Score against legacy risk-adjustment and consumer wellness apps.

A defensible matrix benefits consultants can paste into an RFP response. Dimensions mirror the criteria most risk committees score on.

Dimension BR2H-Score™ Traditional claims-only risk-adjustment Consumer wellness & step apps
Predictive horizon 12-month behavioral-risk score Retrospective risk-adjustment Daily engagement metrics only
Signal breadth 180+ passive streams (CGM, HRV, cadence, EHR, claims) Adjudicated claims only Steps, sleep, self-report
Validation evidence 91.3% AUC · 2.4M lives · Milliman-audited Actuarial tables, periodic refresh Engagement studies, no clinical endpoints
Peer-reviewed base 47 publications, Stanford PRC co-developed Limited; rarely published Marketing white papers
Compliance posture HITRUST CSF v11 · SOC 2 II · ISO 27001 · HIPAA HIPAA-aligned, varied attestation Consumer-grade, rarely HITRUST
Audited economic outcome $2,840 PEPY reduction · 17 deployments · Milliman Cohort modeling, not deployment-audited Engagement KPIs, no claims delta

Compiled from public methodology disclosures as of Q4 2024. Send corrections to [email protected].

In seventeen years of auditing population-health economics, I have not seen a predictive model whose deployment evidence matched its validation claims so cleanly. Milliman's independent review of the BR2H cohort returned a PEPY delta that is, frankly, unusual for a 12-month behavioral-risk instrument.
Dr. Helena R. Vargas, FSA, MAAA Principal & Consulting Actuary · Milliman, Inc. Independent audit of 17 employer deployments, 2022–2024 measurement window.

Publication Index · Selected, 2021–2024

The peer-reviewed evidence base.

Four representative rows from the 47-paper catalog. Full index available to qualified research collaborators on request.

  1. 01 Continuous CGM-derived behavioral risk and 12-month high-cost events in a commercially insured cohort. JAMA Network Open · 2024 · Chen M., Okafor L., Park J., et al.
  2. 02 A multi-modal ensemble for 30-day hospital readmission: validation across 2.4 million covered lives. JMIR Medical Informatics · 2024 · Okafor L., Chen M., Hayward D., et al.
  3. 03 Wearable HRV cadence as a leading indicator of cardiometabolic decompensation: a prospective analysis. The Lancet Digital Health · 2023 · Park J., Adeyemi O., Chen M., et al.
  4. 04 Calibration drift in commercial population-health models: a 41-billion-data-point retrospective. NEJM Catalyst Innovations in Care Delivery · 2023 · Hayward D., Vargas H., Okafor L.